Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller to Board
Summary
Alto Neuroscience appointed Dr. Andrew Miller, founder of Karuna Therapeutics, to its Board of Directors, bringing significant biopharmaceutical leadership and drug development expertise.
Key Events
-
New Board Member Appointed
Dr. Andrew Miller, founder of Karuna Therapeutics, was appointed to the Board of Directors, filling a vacancy created by the board's expansion on March 16, 2026.
-
Strengthened Expertise
Dr. Miller brings extensive experience in biopharmaceutical leadership, drug development, and corporate strategy, having previously served as President of R&D, COO, and CEO of Karuna Therapeutics, which was acquired by Bristol Myers Squibb.
-
Director Compensation
Dr. Miller will receive an initial option grant with a Black-Scholes value up to $400,000, annual option grants up to $200,000, and cash retainers for board and committee service.
Analysis
The appointment of Dr. Andrew Miller, a highly experienced biopharmaceutical executive and founder of Karuna Therapeutics (acquired by Bristol Myers Squibb), significantly strengthens Alto Neuroscience's Board of Directors. His expertise in drug development, corporate strategy, and leadership is crucial for a clinical-stage company, especially following recent clinical trial setbacks. This move enhances strategic oversight and could positively influence future pipeline development and business development efforts.
At the time of this filing, ANRO was trading at $20.44 on NYSE in the Life Sciences sector, with a market capitalization of approximately $717.3M. The 52-week trading range was $2.15 to $28.44. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.